The novel multi-cytokine inhibitor TO-207 specifically inhibits pro-inflammatory cytokine secretion in monocytes without affecting the killing ability of CAR T cells-Reference-Cited by-同舟云学术

The novel multi-cytokine inhibitor TO-207 specifically inhibits pro-inflammatory cytokine secretion in monocytes without affecting the killing ability of CAR T cells

Published:2020-04-22 Issue:4 Volume:15 Page:e0231896
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Futami Muneyoshi^ORCID,Suzuki Keisuke,Kato Satomi,Ohmae Saori,Tahara Yoshio,Nojima Masanori,Imai Yoichi,Mimura Takayuki,Watanabe Yoshihiro,Tojo Arinobu

Funder

Torii Pharmaceutical

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference37 articles.

1. CAR T cell immunotherapy for human cancer;CH June;Science (New York, NY),2018

2. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19;JN Kochenderfer;Blood,2010

3. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia;DL Porter;N Engl J Med,2011

4. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia;SA Grupp;N Engl J Med,2013

5. Chimeric antigen receptor T cells for sustained remissions in leukemia;SL Maude;N Engl J Med,2014

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia;Cancer Immunology, Immunotherapy;2024-04-17

2. Immune Effector Cell-Associated Neurotoxicity Syndrome of Chimeric Antigen Receptor T Cells: From Pathophysiology to Clinical Management;J BIOL REG HOMEOS AG;2024

3. Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures;Frontiers in Immunology;2023-05-25

4. CRISPR/Cas9 and AAV mediated insertion of β2 microglobulin-HLA-G fusion gene protects mesenchymal stromal cells from allogeneic rejection and potentiates the use for off-the-shelf cell therapy;Regenerative Therapy;2022-12

5. Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy;Diseases;2022-07-06